key: cord-0801004-qzqidj69
authors: Singh, S.; Singh, R. K.
title: 'Trained immunity' from Mycobacterium spp. (environmental or BCG) exposure predicts protection from Coronavirus disease 2019 (COVID-19)
date: 2021-02-19
journal: nan
DOI: 10.1101/2021.02.11.20233593
sha: c7d2dddf6bdcb5e0c491dab83c13a910e04de87a
doc_id: 801004
cord_uid: qzqidj69

Endeavors to identify protective variables that could be potentially responsible for reduced COVID-19 impact on certain populations have remained a priority. Multiple attempts have been made to attribute the reduced COVID-19 impact on populations to their bacillus Calmette-Guerin (BCG) vaccination coverage ignoring the fact that the effect of childhood BCG vaccination wanes within the first 5 years of life while most of the COVID-19 cases, as well as deaths, have been observed in adults especially the aged with comorbidities. Since the supposed desired protection being investigated could come from heterologous 'trained immunity' conferred by exposure to Mycobacterium spp. (i.e., environmental and BCG), it is argued that the estimates of the prevalence of 'trained immunity' of populations currently available as latent tuberculosis infection (LTBI) of populations would be a better variable to evaluate such assertions. Indeed, when we analyze the European populations (twenty-four) as well as erstwhile East and West Germany populations completely disregarding their BCG vaccination coverage, the populations with higher trained immunity prevalence consistently display reduced COVID-19 impact as compared to their lower trained immunity prevalence neighbors. The incidences, mortality, and interim case fatality rates (i-CFR) of COVID-19 are found negatively correlated with the trained immunity of populations that have comparable underlying confounders not the BCG coverage per se. It is submitted that to decisively arrive at dependable conclusions about the potential protective benefit that can be gained from BCG vaccination in COVID-19, the ongoing/planned randomized controlled trials should consciously consider including measures of trained immunity as - a) all individuals immunized do not respond equally, b) small study groups of higher background trained immunity could fail to indicate any protective effect.

There have been efforts to understand and explain the differential impact of COVID-19 on populations in pursuance of identifying protective variables that could predict the impact or be applied for intervention. Recent studies in PNAS and Science Advances (1, 2) had endeavored to explain/model the differential effect on populations based on 'trained immunity' correlates of countries' as per bacillus Calmette-Guérin (BCG) vaccination rates after meticulous correction/fitting of the data for supposed major confounders like age, population density, development status, BCG coverage/implementation using the infections and mortality data from an early stage of pandemic (till April 22). More recently, other communications in PNAS (3, 4) have failed to find support for the association previously observed between BCG and the impact of COVID-19 on populations when using updated data set.

The extrapolation of associative observations made previously (1, 2) linking BCG vaccination coverage to reduced COVID-19 impact on populations was expected to disappear (3) (4) (5) as the 'trained immunity' conferred by childhood BCG vaccination usually wanes in <5 years (5-7). Hence, the premise of protective 'trained immunity' from BCG vaccination given in childhood or to children in a population is not supposed to decrease the severity of infection or supposedly provide any protection in currently aged as the BCG conferred 'trained immunity' correlates would have waned away long ago (5-7). The use of early-stage pandemic data (1, 2) when the populations were not evenly exposed along with displayed associations' inherent disconnect with the mechanism proposed behind the observed protective correlation make such assertions untenable.

We reason, the dependability on the correlative associations as well as conclusions presented in refs.

(1-4) would tremendously improve on considerations: a) direct measure of prevailing supposed protective 'trained immunity' correlate (TIC) as a result of populations exposure to Mycobacterium spp. or BCG vaccination (5,6,7), i.e., Tuberculin positivity [TIC of BCG given at birth wanes within <5 years (6), so chances of heterologous protection (8) of elderly from childhood vaccination are remote]; b) analysis of countries at a similar stage of the pandemic; c) underlying confounders including potential contributory variables (e.g., Vitamin D, Zinc) (9,10); d) the correlations observed, at any time, to be the total sum of the effects from protective variable and preventive/curative measures in place (e.g., social distancing norms and adherence, medical infrastructure/support).

The European populations with quite dissimilar BCG coverage (including no vaccination) that have experienced differential COVID-19 impact [11] offer an excellent opportunity to evaluate the alternative hypothesis that the 'trained immunity from Mycobacterium spp. exposure (BCG or environmental NOT . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The analysis of TIC and COVID-19 data from 24 socially similar European countries   support a potential protective role for the prevalent TIC of populations on COVID-19 infections and mortality.

The COVID-19 incidence and mortality data for the European countries (Supp. prevalence estimates (i.e., 'trained immunity' correlate) were from reference (13). All statistical estimations and correlation analysis of the COVID-19 incidence and mortality with TIC or LTBI prevalence of populations (Average, Standard deviation (STDEV), Standard Error (Std. Err.), F-value, Correlation/ Pearson coefficient (r/R), regression, etc) were performed using Microsoft Excel 2019. The p-values <0.05 were considered significant unless explicitly stated otherwise. The methodology employed has been essentially the same as described previously (5,7,9,10).

Analysis of the updated COVID-19 data (till 28 August, Sup. Table 1 LTBI populations consistently displayed lower COVD-19 incidence/mortality per million and interim case fatality rates (i-CFR) (Fig. 1) . The correlations observed shown here are supposed to decline further before the disappearance of COVID-19 due to progressive loss of synchronicity of infections/ pandemic-phases (Sup. Fig. 2 ), lower prevalence of the protective variable (6.06 -15.95%) (13), the differential response of the study population, etc. not necessarily the supposed absence of correlation (3).

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ;

Similarly, East and the West Germany States displayed significant negative covariation of cases, mortality, and i-CFR rates with estimated TIC of populations (22.5% and 9.2% LTBI, respectively) without requiring correction factors (10 April -28 August; Fig. 2 ). Expectedly, the differential response gap seen for East and West Germany is showing signs of closing as expected for populations slowly reaching towards stable equilibrium with underlying confounders (Fig. 2C ).

In conclusion, we believe the incidences, mortality, and i-CFR of COVID-19 would negatively correlate with the trained immunity of populations that have comparable underlying confounders, not the BCG Currently under development COVID-19 vaccines still have a long way to go and be available in sufficient supply to cover the whole global population at the same time to confer the much-needed 'herd immunity' whereas BCG is readily available and may give us respite. Any potential protective effect displayed by BCG vaccination in the ongoing trials, especially in aged and persons with comorbidities who are currently accounting for more than 90% deaths, could help provide hope in the current scenario.

No specific source of funding was utilized for the current study. However, SS acknowledges the funding support to his laboratory from the Institute of Eminence (IoE) seed grant, Banaras Hindu University.

The authors declare no competing interest.

Author contribution: SS designed the research, analyzed the data, and wrote the paper; RK contributed to analysis and drafting. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 for COVID-19 cases and deaths and Sup. Table 3 correlation analysis table) consistently remained negative for the period. The notification rates for countries with >10% LTBI is indicated by broken lines. Correlation remained high with the synchronicity of 1 st peak of infections (see corresponding notification rates graph above for the data date indicated in the table below) and been on decline since then partially resulting from the loss of synchroncity, populations response, acquired immunity and understandably and importantly the changing reporting and management practices. Refer to Sup. Fig. 3 

Note: Countries name in Black from ref 1

Cases per million; DpM: Deaths per million

United States: Institute for Health Metrics and Evaluation (IHME)

COVID-19 data [Cases per million (CpM) and deaths per million DpM

′Trained immunity′ from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes